GE­NEN­TECH SCORE­CARD

Finweek English Edition - - Cover -

»

GOAL To bring at least 20 new mol­e­cules into clin­i­cal de­vel­op­ment. Sta­tus: We added seven new molec­u­lar en­ti­ties into early-stage de­vel­op­ment in 2006, in­clud­ing three small mol­e­cules via col­lab­o­ra­tions. »

GOAL To bring at least 15 ma­jor new prod­ucts or in­di­ca­tions to the mar­ket. Sta­tus: We re­ceived ap­proval for one new prod­uct and seven ad­di­tional in­di­ca­tions for ex­ist­ing prod­ucts in 2006. »

GOAL To achieve a com­pound an­nual non-GAAP earn- ings per share growth rate of 25%. Sta­tus: Our non-GAAP earn­ings per share growth rate for 2006 was 74%. »

GOAL To achieve cu­mu­la­tive free cash flow of US$12bn. Sta­tus: Our free cash flow as of 31 De­cem­ber 2006 was nearly $1bn. »

GOAL To be­come the num­ber one US on­col­ogy com­pany in sales. Sta­tus: We achieved the rank­ing of num­ber one in US on­col­ogy sales in the first quar­ter of 2006 and will strive to main­tain that rank­ing in the fu­ture.

Newspapers in English

Newspapers from South Africa

© PressReader. All rights reserved.